LPCN
Lipocine Inc.Company Information
- Company Name
- Lipocine Inc.
- CIK
- CIK0001535955
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- LPCN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- LPCN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-28
- Last sale
- —
- Shares purchased (TTM)
- 225,561
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,750,125
- Shares outstanding
- 8,216,988
- Ownership
- 33.47%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- 1.88%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 5 | 5 | 5 | 4 | 6 | 3 | 6 | 4 | 6 | 3 | 5 | 4 | ||||||
| Available For Sale Securities Debt Securities Current | 18 | 20 | 10 | 11 | 12 | 16 | 15 | 16 | 17 | 22 | 17 | 20 | ||||||
| Interest Receivable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Contract With Customer Asset Net Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | ||||||
| Assets Current | 24 | 25 | 17 | 16 | 18 | 20 | 22 | 21 | 23 | 25 | 23 | 25 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 24 | 25 | 17 | 16 | 19 | 20 | 23 | 21 | 23 | 25 | 23 | 25 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Warrants And Rights Outstanding | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 2 | 3 | 3 | 2 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 2 | ||||||
| Liabilities | 2 | 3 | 3 | 2 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 2 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 238 | 236 | 224 | 221 | 221 | 221 | 221 | 221 | 221 | 220 | 220 | 220 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -216 | -213 | -209 | -207 | -204 | -202 | -200 | -202 | -199 | -196 | -200 | -197 | ||||||
| Stockholders Equity | 22 | 23 | 14 | 14 | 17 | 19 | 21 | 19 | 21 | 24 | 20 | 22 | ||||||
| Liabilities And Stockholders Equity | 24 | 25 | 17 | 16 | 19 | 20 | 23 | 21 | 23 | 25 | 23 | 25 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 75 | 75 | 75 | 75 | 200 | 200 | 75 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Shares Outstanding | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLipocine Inc. (LPCN) — SEC Financial Statements & Analysis
Lipocine Inc. (LPCN) is a pharmaceutical preparations company, incorporated in DE. Lipocine Inc. trades on Nasdaq as: LPCN. Lipocine Inc. (LPCN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Lipocine Inc. carries a market cap of $21.04M, a P/E ratio of -1.77x, a P/B ratio of 0.97x, a P/S ratio of 13.40x, an enterprise value of $16.06M, and an EV/EBITDA multiple of -1.28x. On profitability, it posts an operating margin of -800.82%, a net margin of -755.13%, a Return on Equity (ROE) of -60.94%, a Return on Assets (ROA) of -55.89%, and a Return on Invested Capital (ROIC) of -89.81%. Per share, it reports EPS of $-1.44, diluted EPS of $-1.44, free cash flow per share of $-1.36, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -62.70% year-over-year, net income growth of 162.94% year-over-year, and EPS growth of 71.26% year-over-year. On the balance sheet, it maintains a current ratio of 11.48x, a quick ratio of 11.39x, working capital of $21.67M, a debt-to-equity ratio of 0.10x, a debt ratio of 0.09, an interest coverage ratio of -660.53x, free cash flow of $-11.19M (TTM), and net debt of $-4.98M. Figures sourced from SEC EDGAR.
- Market Cap
- $21.04M
- P/E TTM
- -1.77x
- EPS TTM
- $-1.44
- P/B TTM
- 0.97x
- ROE TTM
- -60.94%
- ROA TTM
- -55.89%
- Debt To Equity
- 0.10x
- Free Cash Flow TTM
- $-11.19M
- Net Revenue TTM Growth 1Y
- -62.70%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Lipocine Inc. in?
Lipocine Inc. (LPCN) operates in the Pharmaceutical Preparations industry.
What exchange does LPCN trade on?
Lipocine Inc. (LPCN) trades on the Nasdaq.
Where is Lipocine Inc. incorporated?
Lipocine Inc. is incorporated in DE.
When was Lipocine Inc. (LPCN)'s most recent SEC filing?
Lipocine Inc. (LPCN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is LPCN's market cap?
Lipocine Inc. (LPCN) has a market capitalization of $21.04M as of 2026-06-30.
What is LPCN's EPS (earnings per share)?
Lipocine Inc. (LPCN)'s trailing twelve month EPS is $-1.44 as of 2026-06-30.
What is LPCN's ROE (return on equity)?
Lipocine Inc. (LPCN)'s trailing twelve month Return on Equity (ROE) is -60.94% as of 2026-06-30.
What is LPCN's ROA (return on assets)?
Lipocine Inc. (LPCN)'s trailing twelve month Return on Assets (ROA) is -55.89% as of 2026-06-30.
What is LPCN's ROIC (return on invested capital)?
Lipocine Inc. (LPCN)'s trailing twelve month Return on Invested Capital (ROIC) is -89.81% as of 2026-06-30.
What is LPCN's EV/EBITDA?
Lipocine Inc. (LPCN)'s trailing twelve month EV/EBITDA is -1.28x as of 2026-06-30.